4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol has been researched along with Substance Withdrawal Syndrome in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Blount, B; Brown, DC; Giovino, GA; Hendershot, TP; O'Malley, S; Swan, GE | 1 |
Carmella, SG; Hatsukami, DK; Hecht, SS; Hertsgaard, LA; Jensen, JA; Kotlyar, M; Lindgren, BR; Murphy, SE; Stepanov, I | 1 |
1 trial(s) available for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol and Substance Withdrawal Syndrome
Article | Year |
---|---|
Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
Topics: Adolescent; Adult; Aged; Carbon Monoxide; Cotinine; Feasibility Studies; Humans; Middle Aged; Nicotine; Nitrosamines; Pyridines; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco, Smokeless; Young Adult | 2011 |
1 other study(ies) available for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol and Substance Withdrawal Syndrome
Article | Year |
---|---|
PhenX: Host: Biobehavioral measures for tobacco regulatory research.
Topics: Adolescent; Adult; Advisory Committees; Carbon Dioxide; Consensus; Cotinine; Cues; Data Collection; Female; Humans; Male; Nitrosamines; Phenotype; Pregnancy; Research Design; Smokers; Smoking; Software; Substance Withdrawal Syndrome; Tobacco Use | 2020 |